H.Pylori Infection Clinical Trial
Official title:
Relation of Helicobacter Pylori Infection in Patients With Impaired Glucose Tolerance and Their Lipid Profile in Upper Egypt
The primary objective of this study is to : find the relation between H.pylori infection and pre-diabetic patients with lipid profile . Specifically, the study aims to: 1. affect of H.pylori infection in pre-diabetic patients 2. realation between Pre-diabetic patient and lipid profile 3. Risk factor of H.pylori infection in pre-diabetic patients D)HbA1C test measures your average blood sugar level over the past 2 or 3 months. e)Fasting Blood Sugar Test. f) the IgG antibody of h.pylori.
Pre-diabetic state is aphase of impaired glucose tolerance 2 hours Postprandial Glucose (PG) in 75 g oral glucose tolerance test 140 mg/dL-199 mg/dL and/or impaired fasting glucose 100 mg/dL-125 mg/dL and/or HbA1c 5.7-6.4% [5]. Pre-diabetes is pathophysiologically similar to Type II Diabetes with basic defect being insulin resistance and early beta cell failure. The amplitude of large pulses and the rapid oscillations of insulin secretion are lost in pre-diabetes. In pre-diabetes, the glycaemic excursions are usually lower than normaland there is a delay and prolongation in the second phase of insulin secretion [6]. Recent studies have shown that colonisation with H.pylori is associated with increased development of diabetes mellitus [7-11]. A step towards identifying treatable causes of diabetes mellitus will aid the medical health system in developing new strategies in preventing the progression of pre-diabetes to overt diabetes mellitus .Dyslipidemia is a complex disease and a major risk factor foradverse cardiovascular events [12]. High levels of Low Density Lipoproteins (LDL) and low levels of High Density Lipoprotein (HDL) are associated with increased incidence of stoke and myocardial infarction [13]. dyslipidemia also plays a major role in macrovascular complications of Diabetes [14]. There is increasing evidence for the role of H.pylori infection in the initiation, development or persistence of atherosclerosis and coronary heart disease [15,16]. Therefore, exploring the role of treatable causes of dyslipidemia like H.pylorimay help in preventing the progression of dyslipidemia and its adverse effects.The present study aimed to assess the possible role of H.pylori infection on diabetic profile and lipid profile in pre-diabetic patients. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT04550858 -
h.Pylori Ttt With Rebamipide
|
||
| Completed |
NCT03650543 -
Effect of the CYP2C19 Polymorphism in Helicobacter Pylori Eradication
|
Phase 4 | |
| Recruiting |
NCT04022109 -
Screening of Gastric Cancer Via Breath Volatile Organic Compounds by Hybrid Sensing Approach
|
||
| Completed |
NCT05857163 -
Efficacy and Safety of Rifasutenizol (TNP 2198) in Participants With H. Pylori Infection
|
Phase 3 | |
| Not yet recruiting |
NCT05882968 -
Prevalence of H.Pylori in CKD Patients
|
||
| Completed |
NCT03837210 -
Comparative Anti Helicobacter Pylori Efficacy Assessment of Unani Formulation and Quintuple Regimen
|
Phase 2/Phase 3 | |
| Completed |
NCT02332213 -
Volatile Markers in Digestive Cancer
|
||
| Completed |
NCT03592069 -
Concomitant Versus Hybrid Regimen for H. Pylori Eradication
|
Phase 4 | |
| Completed |
NCT06315478 -
Safety and Efficacy of Triple and Quadruple Regimens as First Line Therapy for Management of Helicobacter Pylori Infection in Egyptians
|
Phase 4 | |
| Not yet recruiting |
NCT05951998 -
Frequency of h.Pylori in Children With Dyspeptic Symptoms
|